DR LAL PATHLABS
|
|
BOM : 539524     NSE : LALPATHLAB     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Oct 07,2024 |
Price(EOD): ₹ 3,460.90
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Hospital & Healthcare Services |
MCap: ₹ 28,933.12 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
DR LAL PATHLABS | 4.8% | 1.6% | 38.9% |
APOLLO HOSPITALS ENTERPRISE | -5.9% | -2.3% | 32.3% |
MAX HEALTHCARE INSTITUTE | -6.7% | 3.7% | 56.6% |
GLOBAL HEALTH | -5.9% | -15.4% | 29.4% |
FORTIS HEALTHCARE | -5.8% | 3.1% | 71.2% |
NARAYANA HRUDAYALAYA | -1.6% | -5.1% | 10.3% |
FUNDAMENTAL ANALYSIS OF DR LAL PATHLABS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF DR LAL PATHLABS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
74.84
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 386.50 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 16.09
P/B Calculated based on Book Value of Rs 1,798.13 Cr
[Latest Year - Mar2024 - Consolidated Results ] 12.64
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 2,287.50 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
72% 36% 34% |
SHARE PRICE MOMENTUM OF DR LAL PATHLABS
DR LAL PATHLABS vs SENSEX
DEBT OF DR LAL PATHLABS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.05 0.15 0.24 0.15 |
0.05 0.15 0.24 0.15 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF DR LAL PATHLABS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF DR LAL PATHLABS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
10.36% 17.48% 25.02% 25.64% |
11.26% 16.28% 27.57% 28.95% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
DR LAL PATHLABS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | -3% | -0.7% | 51.3% |
S&P BSE SMALLCAP SELECT INDEX | -4.1% | -1.5% | 42.4% |
S&P BSE 250 SMALLCAP | -4.6% | -4.1% | 41.1% |
S&P BSE 400 MIDSMALLCAP | -5% | -3.5% | 42.9% |
S&P BSE MIDSMALLCAP | -5.1% | -3.9% | 44.8% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY HEALTHCARE | -2.9% | -0.4% | 48.7% |
NIFTY MIDCAP150 QUALITY 50 | -3% | -2% | 32.9% |
NIFTY SMALLCAP250 | -4.8% | -4.4% | 43.2% |
NIFTY MID SMALL400 | -4.9% | -3.4% | 41.4% |
NIFTY500 MULTICAP 50:25:25 | -5.2% | -2.8% | 36.7% |
You may also like the below Video Courses
FAQ about DR LAL PATHLABS
Is DR LAL PATHLABS good for long term investment?
As on Oct 07,2024, the Fundamentals of DR LAL PATHLABS look Strong and hence it may be good for long term investment! See Financial Performance of DR LAL PATHLABS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is DR LAL PATHLABS UnderValued or OverValued?
As on Oct 07,2024, DR LAL PATHLABS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of DR LAL PATHLABS ?
As on Oct 07,2024, the Intrinsic Value of DR LAL PATHLABS is Rs. 2,544.22 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 2,016.76
Fair Value [Median EV / Sales Model] : Rs. 2,544.22
Fair Value [Median Price / Sales Model] : Rs. 2,586.90
Estimated Median Fair Value of DR LAL PATHLABS : Rs. 2,544.22
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.